CA2289847A1 - The use of 1,2,4-triazolo[1,5-c]pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances - Google Patents

The use of 1,2,4-triazolo[1,5-c]pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances Download PDF

Info

Publication number
CA2289847A1
CA2289847A1 CA002289847A CA2289847A CA2289847A1 CA 2289847 A1 CA2289847 A1 CA 2289847A1 CA 002289847 A CA002289847 A CA 002289847A CA 2289847 A CA2289847 A CA 2289847A CA 2289847 A1 CA2289847 A1 CA 2289847A1
Authority
CA
Canada
Prior art keywords
formula
group
alkyl
compounds
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002289847A
Other languages
English (en)
French (fr)
Inventor
Ennio Ongini
Marina Adami
Rosalia Bertorelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2289847A1 publication Critical patent/CA2289847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002289847A 1997-05-21 1998-05-14 The use of 1,2,4-triazolo[1,5-c]pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances Abandoned CA2289847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
ITMI97A001190 1997-05-21
PCT/EP1998/002852 WO1998052568A1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES

Publications (1)

Publication Number Publication Date
CA2289847A1 true CA2289847A1 (en) 1998-11-26

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002289847A Abandoned CA2289847A1 (en) 1997-05-21 1998-05-14 The use of 1,2,4-triazolo[1,5-c]pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances

Country Status (9)

Country Link
EP (1) EP0983068B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002502370A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1255854A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE209492T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU740475B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2289847A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69802679D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1291372B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1998052568A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028621A1 (es) * 2000-05-26 2003-05-14 Schering Corp Antagonistas receptores de adenosina a2a
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CA2430328A1 (en) * 2001-09-28 2003-04-10 Kyowa Hakko Kogyo Co., Ltd. Receptor antagonist
US6653315B2 (en) 2001-10-15 2003-11-25 Schering Corporation Adenosine A2a receptor antagonists
EP1448565B1 (en) 2001-11-30 2009-12-30 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
EP1453836B1 (en) 2001-11-30 2007-03-28 Schering Corporation BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
JP4527712B2 (ja) 2003-04-23 2010-08-18 シェーリング コーポレイション ２−アルキニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニストおよび２−アルケニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニスト
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
EP1888534B1 (en) 2005-06-06 2017-07-26 Intra-Cellular Therapies, Inc. Organic compounds
EP1934227B1 (en) 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2023729B1 (en) 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organic compounds
US9198924B2 (en) 2006-11-13 2015-12-01 Intra-Cellular Therapies, Inc. Organic compounds
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
CN101969774A (zh) 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
US8222259B2 (en) 2008-03-04 2012-07-17 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
WO2010009190A1 (en) * 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
BRPI0922348A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
MA32940B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EP2358204B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
JP2016518343A (ja) 2013-03-15 2016-06-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US9073936B2 (en) 2013-03-15 2015-07-07 Intra-Cellular Therapies, Inc. Organic compounds
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
US10472347B2 (en) 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
KR102562576B1 (ko) 2014-12-06 2023-08-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
WO2019152697A1 (en) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Also Published As

Publication number Publication date
DE69802679D1 (de) 2002-01-10
EP0983068A1 (en) 2000-03-08
ATE209492T1 (de) 2001-12-15
EP0983068B1 (en) 2001-11-28
WO1998052568A1 (en) 1998-11-26
ITMI971190A1 (it) 1998-11-21
ITMI971190A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-05-21
AU7654698A (en) 1998-12-11
AU740475B2 (en) 2001-11-08
IT1291372B1 (it) 1999-01-07
CN1255854A (zh) 2000-06-07
JP2002502370A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
EP0983068B1 (en) THE USE OF 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
AU715380B2 (en) Pyrazolopyrimidines for treatment of neuronal and other disorders
JP6360025B2 (ja) 有機化合物
US20070249638A1 (en) Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments
TW200914048A (en) Combinations for the treatment of B-cell proliferative disorders
US20090053168A1 (en) Treatments of b-cell proliferative disorders
CN113056272A (zh) 新的喹唑啉egfr抑制剂
PT856003E (pt) Analogos heterociclicos 1,2,4-triazolo¬1,5-c|pirimidina tendo actividade antagonista noreceptor a2a de adenosina
JP2013231074A (ja) 新規使用
ES2227522T3 (es) Compuestos aminoalquilo sustituidos.
US20150183791A1 (en) IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
JP2015517565A (ja) 疼痛の治療のためのジヌクレオシドポリリン酸
Baraldi et al. Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes?
JPH09221423A (ja) 薬物依存形成抑制剤
AU2007288312A1 (en) KW-3902 conjugates that do not cross the blood-brain barrier
JP2002543133A (ja) ロフルミラストおよびｐｄｅ−３インヒビターを含有する共力薬の組合せ物
KR20180081595A (ko) 이소성 지방 축적의 치료에 사용하기 위한 a3 아데노신 수용체 리간드
KR20070008689A (ko) 아데노신 ａ１ 수용체 길항제 및 알도스테론 억제제를포함하는 병용 요법
MXPA99010735A (en) THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
JPS627167B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK40054977A (en) Novel quinazoline egfr inhibitors
ES2260061T3 (es) Composiciones farmaceuticas para trastornos relacionados con la alimentacion.
JPWO2003061700A1 (ja) 慢性腎疾患治療薬
JPWO2005072739A1 (ja) 片頭痛の治療剤
WO2002090358A1 (en) Disubstituted 7,9-guaninium halides as telomerase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued